Forticell Bioscience, Inc. Announces Collaboration Agreement with CJ CheilJedang, a Korean Pharmaceutical Giant to Use Fibrin MicroBeads (FMB(TM)) for Novel Umbilical Cord Blood Stem Cell Recovery
Published: Jan 14, 2008
NEW YORK--(BUSINESS WIRE)--Forticell Bioscience, Inc. (OTCBB: FORB - News) announced today that it has entered into a Material Transfer and Technology Evaluation Agreement with CJ CheilJedang. (CJ), one of the largest Food and Healthcare companies in South Korea, granting CJ the exclusive right for a limited time to use it’s Fibrin MicroBeads (FMB™) technology for the extraction and expansion of mesenchymal-type stem cells (MSC) from human umbilical cord blood (UCB). Its wholly owned subsidiary, Hapto Biotech, Inc.